Drug Profile
Ravidasvir - Presidio Pharmaceuticals/XTL Biopharmaceuticals
Alternative Names: ASC-16; Asclevir; BI-238630; C5; PPI-668Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator XTL Biopharmaceuticals
- Developer Ascletis; Drugs for Neglected Diseases Initiative Foundation; European Egyptian Pharmaceutical Industries; Ministry of Public Health (Thailand); Pharco Corporation; Presidio Pharmaceuticals
- Class Antivirals; Benzimidazoles; Carbamates; Naphthalenes; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
- Phase II/III COVID 2019 infections
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Australia (PO, Tablet)
- 28 Jun 2022 Launched for Hepatitis C (Combination therapy, Treatment-naive) in China (PO)
- 29 Jul 2021 Chemical structure information added